<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02752412</url>
  </required_header>
  <id_info>
    <org_study_id>EFC14113</org_study_id>
    <secondary_id>U1111-1176-8378</secondary_id>
    <nct_id>NCT02752412</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of LixiLan Versus Insulin Glargine Alone Both With Metformin in Japanese With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Drugs</brief_title>
  <acronym>LIXILAN JP-L</acronym>
  <official_title>A Randomized, Active-controlled, Open Label, 2-treatment Arm, and Multicenter Study Comparing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Combination to Insulin Glargine With Metformin in Japanese Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Drugs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      To compare LixiLan to insulin glargine in glycated hemoglobin (HbA1c) change from baseline to
      week 26 in patients with type 2 diabetes mellitus.

      Secondary Objective:

      To compare overall efficacy and safety of LixiLan to insulin glargine over 26 weeks in
      patients with type 2 diabetes mellitus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The maximum study duration per patient will be approximately 41 weeks: an up to 14-week
      screening period (consisting of an up to 2-week screening phase and a 12-week run-in phase),
      a 26-week randomized treatment period, and a 3-day post-treatment safety follow-up period.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 17, 2016</start_date>
  <completion_date type="Anticipated">October 3, 2018</completion_date>
  <primary_completion_date type="Anticipated">October 3, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in HbA1c</measure>
    <time_frame>Baseline, 26 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients reaching HbA1c &lt;7% or ≤6.5%</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in 2-hour postprandial plasma glucose (PPG) during standardized meal test</measure>
    <time_frame>Baseline, 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in blood glucose excursion during standardized meal test</measure>
    <time_frame>Baseline, 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in 7-point self-monitoring plasma glucose (SMPG) profiles (each time point and average daily value)</measure>
    <time_frame>Baseline, 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in body weight</measure>
    <time_frame>Baseline, 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in FPG</measure>
    <time_frame>Baseline, 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in daily dose of insulin glargine</measure>
    <time_frame>Baseline, 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients reaching HbA1c &lt;7% with no body weight gain</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients reaching HbA1c &lt;7% with no body weight gain and with no documented (PG ≤70 mg/dL [3.9 mmol/L]) symptomatic hypoglycemia</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients reaching HbA1c &lt;7% with no documented (PG ≤70 mg/dL [3.9 mmol/L]) symptomatic hypoglycemia</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients requiring a rescue therapy</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hypoglycemic events</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of anti-lixisenatide antibodies from baseline</measure>
    <time_frame>Baseline, 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of anti-insulin antibodies from baseline</measure>
    <time_frame>Baseline, 26 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">534</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>LixiLan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LixiLan (insulin glargine/lixisenatide fixed ratio combination) is injected subcutaneously (under the skin) once daily. Dose is individually adjusted.
Metformin will be continued.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>insulin glargine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Insulin glargine U100 (Lantus) will be injected subcutaneously (under skin) once daily. Dose will be individually adjusted.
Metformin will be continued.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin glargine/Lixisenatide (HOE901/AVE0010)</intervention_name>
    <description>Pharmaceutical form: solution
Route of administration: subcutaneous</description>
    <arm_group_label>LixiLan</arm_group_label>
    <other_name>LixiLan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin glargine U100 (HOE901)</intervention_name>
    <description>Pharmaceutical form: solution
Route of administration: subcutaneous</description>
    <arm_group_label>insulin glargine</arm_group_label>
    <other_name>Lantus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Pharmaceutical form: tablet
Route of administration: oral</description>
    <arm_group_label>insulin glargine</arm_group_label>
    <arm_group_label>LixiLan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :

          -  Patient with type 2 diabetes mellitus (T2DM) diagnosed for at least 1 year before the
             screening visit (V1).

          -  Patient treated with a stable, once a day basal insulin regimen (ie, type of insulin
             and time/frequency of the injection), for at least 3 months before the screening
             visit.

          -  The total daily basal insulin dose should be stable (± 20%) and &lt;15 U/day for at least
             1 month before the screening visit.

          -  Patient receiving 1 or 2 oral anti-diabetic drugs (OADs): the OAD dose(s) must be
             stable during the 3 months before the screening visit. The OADs can be 1 to 2 out of:

          -  Metformin;

          -  Sulfonylurea (SU);

          -  Glinide;

          -  Dipeptidyl-peptidase-4 (DPP-4) inhibitor;

          -  Sodium glucose co-transporter 2 (SGLT2) inhibitor;

          -  Alpha glucosidase inhibitor (alpha-GI).

          -  Signed written informed consent.

        Exclusion criteria:

          -  Age &lt;20 years at screening visit.

          -  HbA1c at screening visit &lt;7.5% or &gt;9.5%.

          -  Fasting plasma glucose (FPG) &gt;180 mg/dL (10.0 mmol/L) at screening visit.

          -  Pregnancy or lactation, women of childbearing potential with no effective
             contraceptive method.

          -  Use of oral or injectable glucose-lowering agents other than those stated in the
             inclusion criteria in the 3 months before screening visit.

          -  Previous use of insulin regimen other than basal insulin, eg, prandial or pre-mixed
             insulin.

        Note: Short-term treatment (≤10 days) due to intercurrent illness including gestational
        diabetes is allowed at the discretion of the Investigator.

          -  Use of thiazolidinedione (TZD) within 6 months prior to screening visit.

          -  History of discontinuation of a previous treatment with a glucagon-like
             peptide-1(GLP-1) receptor agonist due to safety/ tolerability issues or lack of
             efficacy.

          -  Laboratory findings at the screening visit; including:

          -  Amylase and/or lipase &gt;3 times the upper limit of the normal (ULN) laboratory range;

          -  Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &gt;3 ULN;

          -  Calcitonin ≥20 pg/mL (5.9 pmol/L);

          -  Positive serum pregnancy test.

          -  Any contraindication to metformin use according to local labeling.

          -  History of hypersensitivity to any GLP-1 receptor agonist or to metacresol.

          -  Contraindication to use of insulin glargine or lixisenatide according to local
             labeling. History of hypersensitivity to insulin glargine or to any of the excipients.

          -  Personal or immediate family history of medullary thyroid cancer (MTC) or genetic
             condition that predisposes to MTC (eg, multiple endocrine neoplasia syndromes).

          -  History of pancreatitis (unless pancreatitis was related to gallstones and
             cholecystectomy has now been performed), pancreatitis during previous treatment with
             incretin therapies, chronic pancreatitis, pancreatectomy, stomach/gastric surgery.

          -  Exclusion criteria for randomization at the end of the run-in phase:

          -  HbA1c &lt;7.5% or &gt;9.5% at visit 6 (Week -1).

          -  Mean fasting self monitored plasma glucose (SMPG) &gt;160 mg/dL (8.9 mmol/L), calculated
             from all available (minimum of 4 self-measurements) values during the 7 days prior to
             randomization.

        Note:fasting SMPG on the day of randomization can be included if assessed before
        randomization.

          -  Average insulin glargine daily dose ≥15 U/day or &lt;5U/day calculated for the last 3
             days before Visit 7.

          -  Metformin total daily dose &lt;750 mg/day.

          -  Amylase and/or lipase &gt;3 ULN at Visit 6 (Week -1).

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>For site information, send an email with site number to</last_name>
    <email>Contact-Us@sanofi.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Investigational Site Number 392002</name>
      <address>
        <city>Adachi-Ku</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392132</name>
      <address>
        <city>Annaka-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392009</name>
      <address>
        <city>Arakawa-Ku</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392152</name>
      <address>
        <city>Asahikawa-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392025</name>
      <address>
        <city>Atsugi-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392024</name>
      <address>
        <city>Chiba-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392151</name>
      <address>
        <city>Chiba-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392011</name>
      <address>
        <city>Chigasaki-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392013</name>
      <address>
        <city>Chiyoda-Ku</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392052</name>
      <address>
        <city>Chiyoda-Ku</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392003</name>
      <address>
        <city>Chuo-Ku</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392017</name>
      <address>
        <city>Chuo-Ku</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392055</name>
      <address>
        <city>Chuo-Ku</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392008</name>
      <address>
        <city>Fujimi-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392143</name>
      <address>
        <city>Fujisawa-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392094</name>
      <address>
        <city>Fukuoka-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392147</name>
      <address>
        <city>Fukuoka-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392100</name>
      <address>
        <city>Gifu-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392059</name>
      <address>
        <city>Hachioji-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392048</name>
      <address>
        <city>Hamamatsu-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392102</name>
      <address>
        <city>Hamamatsu-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392123</name>
      <address>
        <city>Higashiosaka-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392135</name>
      <address>
        <city>Higashiosaka-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392079</name>
      <address>
        <city>Hiki-Gun</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392141</name>
      <address>
        <city>Himeji-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392057</name>
      <address>
        <city>Iruma-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392022</name>
      <address>
        <city>Ise-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392020</name>
      <address>
        <city>Izumisano-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392139</name>
      <address>
        <city>Kagoshima-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392036</name>
      <address>
        <city>Kamakura-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392136</name>
      <address>
        <city>Kamogawa-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392066</name>
      <address>
        <city>Kashiwa-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392045</name>
      <address>
        <city>Kashiwara-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392006</name>
      <address>
        <city>Kasugai-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392149</name>
      <address>
        <city>Kasugai-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392053</name>
      <address>
        <city>Kawagoe-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392065</name>
      <address>
        <city>Kawagoe-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392007</name>
      <address>
        <city>Kawaguchi-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392062</name>
      <address>
        <city>Kawaguchi-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392090</name>
      <address>
        <city>Kawaguchi-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392077</name>
      <address>
        <city>Kawasaki-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392082</name>
      <address>
        <city>Kawasaki-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392142</name>
      <address>
        <city>Kawasaki-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392010</name>
      <address>
        <city>Kisarazu-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392016</name>
      <address>
        <city>Kisarazu-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392031</name>
      <address>
        <city>Kitakyushu-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392068</name>
      <address>
        <city>Kitakyushu-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392041</name>
      <address>
        <city>Kitakyusyu-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392086</name>
      <address>
        <city>Kobe-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392044</name>
      <address>
        <city>Koga-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392001</name>
      <address>
        <city>Koriyama-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392028</name>
      <address>
        <city>Kumamoto-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392092</name>
      <address>
        <city>Kumamoto-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392108</name>
      <address>
        <city>Kumamoto-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392116</name>
      <address>
        <city>Kumamoto-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392099</name>
      <address>
        <city>Kushiro-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392049</name>
      <address>
        <city>Kyoto-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392107</name>
      <address>
        <city>Kyoto-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392088</name>
      <address>
        <city>Maebashi-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392158</name>
      <address>
        <city>Maebashi-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392121</name>
      <address>
        <city>Matsuyama-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392122</name>
      <address>
        <city>Minato-Ku</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392076</name>
      <address>
        <city>Misato-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392014</name>
      <address>
        <city>Mitaka-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392042</name>
      <address>
        <city>Mito-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392043</name>
      <address>
        <city>Mito-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392078</name>
      <address>
        <city>Mito-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392046</name>
      <address>
        <city>Miyazaki-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392026</name>
      <address>
        <city>Nagoya-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392101</name>
      <address>
        <city>Nagoya-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392128</name>
      <address>
        <city>Nagoya-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392131</name>
      <address>
        <city>Nagoya-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392134</name>
      <address>
        <city>Nagoya-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392137</name>
      <address>
        <city>Nagoya-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392140</name>
      <address>
        <city>Nagoya-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392154</name>
      <address>
        <city>Naka-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392050</name>
      <address>
        <city>Niihama-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392159</name>
      <address>
        <city>Obihiro-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392145</name>
      <address>
        <city>Ogaki-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392153</name>
      <address>
        <city>Oita-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392005</name>
      <address>
        <city>Okawa-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392071</name>
      <address>
        <city>Okayama-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392080</name>
      <address>
        <city>Okayama-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392095</name>
      <address>
        <city>Onga-Gun</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392105</name>
      <address>
        <city>Osaka-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392117</name>
      <address>
        <city>Osaka-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392144</name>
      <address>
        <city>Osaka-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392125</name>
      <address>
        <city>Osaki-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392120</name>
      <address>
        <city>Ota-Ku</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392157</name>
      <address>
        <city>Ota-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392040</name>
      <address>
        <city>Oyama-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392038</name>
      <address>
        <city>Sagamihara-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392069</name>
      <address>
        <city>Saijo-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392030</name>
      <address>
        <city>Saitama-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392058</name>
      <address>
        <city>Saitama-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392074</name>
      <address>
        <city>Sanda-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392047</name>
      <address>
        <city>Sapporo-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392106</name>
      <address>
        <city>Sapporo-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392097</name>
      <address>
        <city>Sasebo-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392015</name>
      <address>
        <city>Satsumasendai-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392004</name>
      <address>
        <city>Sendai-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392034</name>
      <address>
        <city>Shimotsuke-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392110</name>
      <address>
        <city>Shinagawa-Ku</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392021</name>
      <address>
        <city>Shinjuku-Ku</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392098</name>
      <address>
        <city>Shinjuku-Ku</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392104</name>
      <address>
        <city>Shiogama-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392037</name>
      <address>
        <city>Shizuoka-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392081</name>
      <address>
        <city>Shizuoka-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392019</name>
      <address>
        <city>Shobara-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392018</name>
      <address>
        <city>Shunan-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392027</name>
      <address>
        <city>Suita-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392056</name>
      <address>
        <city>Taito-Ku</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392051</name>
      <address>
        <city>Takatsuki-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392156</name>
      <address>
        <city>Takatsuki-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392061</name>
      <address>
        <city>Tokorozawa-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392111</name>
      <address>
        <city>Tomakomai-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392073</name>
      <address>
        <city>Tsu-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392063</name>
      <address>
        <city>Ube-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392124</name>
      <address>
        <city>Ushiku-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392067</name>
      <address>
        <city>Yatsushiro-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392085</name>
      <address>
        <city>Yokohama-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392126</name>
      <address>
        <city>Yokohama-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392035</name>
      <address>
        <city>Zentsuji-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 20, 2016</study_first_submitted>
  <study_first_submitted_qc>April 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2016</study_first_posted>
  <last_update_submitted>May 14, 2018</last_update_submitted>
  <last_update_submitted_qc>May 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Lixisenatide</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
    <mesh_term>Hypoglycemic Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

